card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Anatomic Pathology Lab Services

I-O clinical development podcast series
Anatomic Pathology Lab Services
Home / Insights / Anatomic Pathology Lab Services



Anatomic Pathology plays an important role in biomarker selection and companion diagnostics. This episode describes three key challenges in immuno-oncology development related to anatomic pathology. Some of the key issues organizations that support clinical trials I-O drug development face, particularly with companion diagnostics, involve ensuring the sample availability is adequate and appropriate for the different clinical trials, that the assay outcome is useful, and the results are relevant for the clinical trials. Many assays for the determination of PD-L1 status in most tumor types are based on immunohistochemistry, or IHC. Also, companion diagnostic strategies that are using multiple PD-L1 clones for related drugs in development are rapidly evolving.

Having adequate tissue samples is one of the most critical components; or “tissue is the issue.” It's also important that the sites that are sending samples have the ability to process samples in a timely manner, establishing that the fixation and other pre-analytical conditions that influence the outcome of the results are well evaluated. The podcast reviews our solutions that strive to make the whole process easier for patients and doctors alike.